Article info
Cardiac risk factors and prevention
Original research article
Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis
- Correspondence to Dr Sheyu Li, Department of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China and Division of Population Health & Genomics, Ninewells Hospital and School of Medicine, University of Dundee, Dundee, DD1 9SY, Scotland, UK; lisheyu{at}gmail.com
Citation
Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis
Publication history
- Received January 16, 2019
- Revised January 28, 2019
- Accepted January 30, 2019
- First published March 6, 2019.
Online issue publication
January 18, 2021
Article Versions
- Previous version (18 January 2021).
- Previous version (18 January 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.